|Day Low/High||79.37 / 80.84|
|52 Wk Low/High||77.92 / 120.37|
Some of this month's most explosive moves are coming from large-cap stocks. Here's how to profit from five of them.
It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.
There were many earnings reports today, and many could've been worse, Cramer says.
A wave of key earnings report out overnight and this morning swept Wall Street away on Tuesday.
Stocks fluctuate Tuesday as crude closes under $43 a barrel for the first time since April.
United Technologies is taking share from competitors like General Electirc.
Gilead Sciences (GILD) stock is retreating Tuesday afternoon after the company lowered its full-year sales outlook.
TheStreet highlights 3 stocks pushing the health care sector lower today.
Good enough, tied with a good story, is pushing post-earnings bumps today.
Stocks trade mixed Tuesday as a number of positive and negative earnings report keep traders active.
When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.
Stock futures are mixed as investors stay on the sidelines ahead of the kickoff to the Federal Reserve's July meeting.
One is rising on a minor sales bump while the other is falling despite solid results; and here is why.
With chaos blaring in the headlines, market players simple shrug.
The stock is poised to test support at around $78 per share, or 10% lower. At that point, Gilead stock is safe to buy. Anything in between is trap.
Trade-Ideas LLC identified Gilead (GILD) as a post-market laggard candidate
Gilead's stock trades at a discount to other biotech peers because its drug research pipeline lacks the blockbusters needed to make up for slowing sales from its hepatitis C franchise.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2016.
Earnings reports will test the timeframe mettle for some investors and traders.
The biopharmaceutical giant is getting ready to report its second-quarter results, which are set to be released after Monday's close.
Verizon won the competitive bidding process for Yahoo and will pay the company $4.8 billion for its internet properties.
Verizon strikes a $4.8 billion deal to acquire Yahoo!'s core operations, while Tesla and SolarCity are closer to a merger agreement.
A slew of corporate earnings and closely watched Federal Reserve meeting are in focus for the week of July 25.
The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.
Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.
Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?
Gilead Sciences (GILD) is scheduled to report earnings on Monday, July 25 after the market close.